Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Daniel Botelho Costa, M.D.

Co-Author

This page shows the publications co-authored by Daniel Costa and Paul Vanderlaan.
Connection Strength

7.853
  1. VanderLaan PA, Rangachari D, Costa DB. Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018 09 13; 379(11):1093.
    View in: PubMed
    Score: 0.883
  2. VanderLaan PA, Rangachari D, Majid A, Parikh MS, Gangadharan SP, Kent MS, McDonald DC, Huberman MS, Kobayashi SS, Costa DB. Tumor biomarker testing in non-small-cell lung cancer: A decade of change. Lung Cancer. 2018 02; 116:90-95.
    View in: PubMed
    Score: 0.842
  3. VanderLaan PA, Rangachari D, Mockus SM, Spotlow V, Reddi HV, Malcolm J, Huberman MS, Joseph LJ, Kobayashi SS, Costa DB. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. Lung Cancer. 2017 04; 106:17-21.
    View in: PubMed
    Score: 0.789
  4. Vanderlaan PA, Yamaguchi N, Folch E, Boucher DH, Kent MS, Gangadharan SP, Majid A, Goldstein MA, Huberman MS, Kocher ON, Costa DB. Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. Lung Cancer. 2014 Apr; 84(1):39-44.
    View in: PubMed
    Score: 0.641
  5. Rangachari D, To C, Shpilsky JE, VanderLaan PA, Kobayashi SS, Mushajiang M, Lau CJ, Paweletz CP, Oxnard GR, Jänne PA, Costa DB. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. J Thorac Oncol. 2019 11; 14(11):1995-2002.
    View in: PubMed
    Score: 0.235
  6. Sehgal K, Peters MLB, VanderLaan PA, Rangachari D, Kobayashi SS, Costa DB. Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer. J Thorac Oncol. 2019 01; 14(1):e1-e3.
    View in: PubMed
    Score: 0.218
  7. VanderLaan PA, Chen Y, DiStasio M, Rangachari D, Costa DB, Heher YK. Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving Target. Clin Lung Cancer. 2018 09; 19(5):e589-e590.
    View in: PubMed
    Score: 0.215
  8. Rangachari D, VanderLaan PA, Costa DB. Updated Correlation of 22C3-PD-L1 =50% Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor-Resistant Setting. J Thorac Oncol. 2018 05; 13(5):e81-e83.
    View in: PubMed
    Score: 0.215
  9. Shea M, Rangachari D, Hallowell RW, Hollie NI, Costa DB, VanderLaan PA. Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis. Cancer Treat Res Commun. 2018; 15:17-20.
    View in: PubMed
    Score: 0.212
  10. Torous VF, Rangachari D, Gallant BP, Shea M, Costa DB, VanderLaan PA. PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option? J Am Soc Cytopathol. 2018 May-Jun; 7(3):133-141.
    View in: PubMed
    Score: 0.212
  11. Carney BJ, Rangachari D, VanderLaan PA, Gowen K, Schrock AB, Ali SM, Costa DB. De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma. Lung Cancer. 2017 12; 114:108-110.
    View in: PubMed
    Score: 0.205
  12. Rangachari D, Le X, Shea M, Huberman MS, VanderLaan PA, Kobayashi SS, Costa DB. Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy. J Thorac Oncol. 2017 11; 12(11):e175-e177.
    View in: PubMed
    Score: 0.202
  13. DiStasio M, Chen Y, Rangachari D, Costa DB, Heher YK, VanderLaan PA. Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis. Clin Lung Cancer. 2017 09; 18(5):e349-e356.
    View in: PubMed
    Score: 0.199
  14. Rangachari D, VanderLaan PA, Shea M, Le X, Huberman MS, Kobayashi SS, Costa DB. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 =50% Expression in Lung Adenocarcinoma. J Thorac Oncol. 2017 05; 12(5):878-883.
    View in: PubMed
    Score: 0.197
  15. Rangachari D, Drake L, Huberman MS, McDonald DC, VanderLaan PA, Folch E, Costa DB. Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practice. Cancer Treat Commun. 2016; 9:41-43.
    View in: PubMed
    Score: 0.190
  16. Lucena-Araujo AR, Moran JP, VanderLaan PA, Dias-Santagata D, Folch E, Majid A, Kent MS, Gangadharan SP, Rangachari D, Huberman MS, Kobayashi SS, Costa DB. De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers. Lung Cancer. 2016 09; 99:17-22.
    View in: PubMed
    Score: 0.189
  17. Sheikine Y, Rangachari D, McDonald DC, Huberman MS, Folch ES, VanderLaan PA, Costa DB. EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review. Clin Lung Cancer. 2016 11; 17(6):483-492.
    View in: PubMed
    Score: 0.189
  18. Gao X, VanderLaan PA, Bailey AS, Costa DB. Comprehensive Genomic Profiling Differentiates Metachronous Primary Small-Cell Lung Cancer From Late Recurrence. Clin Lung Cancer. 2016 09; 17(5):e169-e172.
    View in: PubMed
    Score: 0.186
  19. Jorge SE, Schulman S, Freed JA, VanderLaan PA, Rangachari D, Kobayashi SS, Huberman MS, Costa DB. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. Lung Cancer. 2015 Dec; 90(3):369-74.
    View in: PubMed
    Score: 0.181
  20. Folch E, Costa DB, Wright J, VanderLaan PA. Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis. Transl Lung Cancer Res. 2015 Aug; 4(4):392-403.
    View in: PubMed
    Score: 0.178
  21. Le X, Freed JA, VanderLaan PA, Huberman MS, Rangachari D, Jorge SE, Lucena-Araujo AR, Kobayashi SS, Balasubramanian S, He J, Chudnovsky Y, Miller VA, Ali SM, Costa DB. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling. Clin Lung Cancer. 2015 Sep; 16(5):e105-9.
    View in: PubMed
    Score: 0.174
  22. Le X, Desai NV, Majid A, Karp RS, Huberman MS, Rangachari D, Kent MS, Gangadharan SP, Folch E, VanderLaan PA, Costa DB. De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors. Lung Cancer. 2015 Apr; 88(1):70-3.
    View in: PubMed
    Score: 0.172
  23. Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, Uhlmann EJ, Wong ET, Dahlberg SE, Huberman MS, Costa DB. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer. 2015 Apr; 88(1):108-11.
    View in: PubMed
    Score: 0.172
  24. Rangachari D, VanderLaan PA, Le X, Folch E, Kent MS, Gangadharan SP, Majid A, Haspel RL, Joseph LJ, Huberman MS, Costa DB. Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice. Cancer Treat Commun. 2015; 4:174-181.
    View in: PubMed
    Score: 0.171
  25. Yamaguchi N, Vanderlaan PA, Folch E, Boucher DH, Canepa HM, Kent MS, Gangadharan SP, Majid A, Kocher ON, Goldstein MA, Huberman MS, Costa DB. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. Lung Cancer. 2013 Oct; 82(1):31-7.
    View in: PubMed
    Score: 0.155
  26. Srivastava N, VanderLaan PA, Kelly CP, Costa DB. Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer. J Thorac Oncol. 2013 Mar; 8(3):e23-4.
    View in: PubMed
    Score: 0.150
  27. Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova EV, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, Nishino M, Nagy RJ, Lanman RB, Capelletti M, Chambers ES, Redig AJ, VanderLaan PA, Costa DB, Imamura Y, Jänne PA. Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2018 12 01; 24(23):5963-5976.
    View in: PubMed
    Score: 0.055
  28. Ostios-Garcia L, Faig J, Leonardi GC, Adeni AE, Subegdjo SJ, Lydon CA, Rangachari D, Huberman MS, Sehgal K, Shea M, VanderLaan PA, Cheng MP, Marty FM, Hammond SP, Costa DB, Awad MM. Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 07; 13(7):1037-1042.
    View in: PubMed
    Score: 0.054
  29. Heidinger BH, Anderson KR, Nemec U, Costa DB, Gangadharan SP, VanderLaan PA, Bankier AA. Morphologic characteristics of pulmonary adenocarcinomas manifesting as pure ground-glass nodules on CT. J Thorac Dis. 2017 Dec; 9(12):E1148-E1150.
    View in: PubMed
    Score: 0.052
  30. Heidinger BH, Nemec U, Anderson KR, Costa DB, Gangadharan SP, VanderLaan PA, Bankier AA. "Rounding" the Size of Pulmonary Nodules: Impact of Rounding Methods on Nodule Management, as Defined by the 2017 Fleischner Society Guidelines. Acad Radiol. 2017 11; 24(11):1422-1427.
    View in: PubMed
    Score: 0.051
  31. Heidinger BH, Anderson KR, Nemec U, Costa DB, Gangadharan SP, VanderLaan PA, Bankier AA. Lung Adenocarcinoma Manifesting as Pure Ground-Glass Nodules: Correlating CT Size, Volume, Density, and Roundness with Histopathologic Invasion and Size. J Thorac Oncol. 2017 08; 12(8):1288-1298.
    View in: PubMed
    Score: 0.050
  32. Heidinger BH, Anderson KR, Moriarty EM, Costa DB, Gangadharan SP, VanderLaan PA, Bankier AA. Size Measurement and T-staging of Lung Adenocarcinomas Manifesting as Solid Nodules =30?mm on CT: Radiology-Pathology Correlation. Acad Radiol. 2017 07; 24(7):851-859.
    View in: PubMed
    Score: 0.050
  33. Klempner SJ, Ou SH, Costa DB, VanderLaan PA, Sanford EM, Schrock A, Gay L, Ali SM, Miller VA. The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review. Clin Lung Cancer. 2015 Sep; 16(5):334-339.e1.
    View in: PubMed
    Score: 0.043
  34. Cai Y, Hirata A, Nakayama S, VanderLaan PA, Levantini E, Yamamoto M, Hirai H, Wong KK, Costa DB, Watanabe H, Kobayashi SS. CCAAT/enhancer binding protein ß is dispensable for development of lung adenocarcinoma. PLoS One. 2015; 10(3):e0120647.
    View in: PubMed
    Score: 0.043
  35. Niederst MJ, Sequist LV, Poirier JT, Mermel CH, Lockerman EL, Garcia AR, Katayama R, Costa C, Ross KN, Moran T, Howe E, Fulton LE, Mulvey HE, Bernardo LA, Mohamoud F, Miyoshi N, VanderLaan PA, Costa DB, Jänne PA, Borger DR, Ramaswamy S, Shioda T, Iafrate AJ, Getz G, Rudin CM, Mino-Kenudson M, Engelman JA. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun. 2015 Mar 11; 6:6377.
    View in: PubMed
    Score: 0.043
  36. Folch E, Yamaguchi N, VanderLaan PA, Kocher ON, Boucher DH, Goldstein MA, Huberman MS, Kent MS, Gangadharan SP, Costa DB, Majid A. Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer. J Thorac Oncol. 2013 Nov; 8(11):1438-1444.
    View in: PubMed
    Score: 0.039
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.